iSpecimen Inc. Receives Nasdaq Notice; Extension to Regain Listing Compliance

What Happened
iSpecimen Inc. announced on Sept. 8, 2026 that Nasdaq’s Listing Qualifications Department issued a Deficiency Letter and granted the company an extension until Nov. 25, 2026 to evidence compliance with Nasdaq Listing Rule 5550(b) (minimum stockholders’ equity). Nasdaq first notified the company of non-compliance on May 29, 2026. iSpecimen submitted compliance plans on July 13, Aug. 6 and Sept. 4, 2026 and cited a May 11, 2026 private placement that raised roughly $2.5 million and a planned best-efforts public offering targeting approximately $5 million in gross proceeds. The company provided projections showing about $5.1 million in stockholders’ equity through June 30, 2027.

Key Details

• Nasdaq extension deadline to evidence compliance: November 25, 2026.
• Nasdaq Listing Rule 5550(b) minimums: $2,500,000 stockholders’ equity (or alternatives).
• Transactions cited: May 11, 2026 private placement (~$2.5M gross) and a planned ~ $5M best-efforts public offering.
• Company projection: approximately $5.1M stockholders’ equity through June 30, 2027; Nasdaq will continue to monitor and trading is not immediately affected.

Why It Matters
This filing signals a material listing risk: if iSpecimen does not show compliance by the deadline or in its next periodic report, Nasdaq could begin delisting proceedings (with an appeal right). The company’s remediation relies on capital raises (which may dilute existing shareholders) and on achieving the equity threshold; there is no assurance the planned offering will close or be sufficient. Investors should monitor upcoming filings (including any 8-K or periodic reports) for definitive transactions, a recent balance sheet or pro forma evidence of compliance and updates on the planned public offering.